PI Industries Limited has informed the Exchange about Transcript of the Earnings Conference Call held on May 20, 2026

PI Industries reported FY26 full-year revenue of Rs 67,137 million with EBITDA margins of 25% and a strong net cash position of Rs 34,265 million. The AgChem export business faced headwinds due to global industry contraction and lower volumes, though 5 new molecules were commercialized contributing 18% of exports. The Pharma segment delivered 40% growth and is targeting Rs 500-600 crore revenue to turn EBITDA positive in 2-3 years. The company launched its first NCE molecule 'Pioxaniliprole' domestically and is targeting global filings by end of FY27. Management guided for positive revenue growth in FY27, with capex of Rs 700-800 crore, and expects to maintain gross margins while managing input cost volatility. The order book stands at approximately $1-1.2 billion.